Relif en es it fr

Relif Brand names, Relif Analogs

Relif Brand Names Mixture

  • No information avaliable

Relif Chemical_Formula


Relif RX_link

Relif fda sheet

Relif FDA

Relif msds (material safety sheet)

Relif MSDS

Relif Synthesis Reference

No information avaliable

Relif Molecular Weight

232.235 g/mol

Relif Melting Point

229.5 oC

Relif H2O Solubility

100 mg/L

Relif State


Relif LogP


Relif Dosage Forms

Suspension (250 mg/5 mL tsp); Tablets (1000 mg, 500 mg, 250 mg)

Relif Indication

For the treatment of urinary tract infections caused by susceptible gram-negative microorganisms, including the majority of E. Coli, Enterobacter species, Klebsiella species, and Proteus species.

Relif Pharmacology

Nalidixic acid is a quinolone antibacterial agent for oral administration. Nalidixic acid has marked antibacterial activity against gram-negative bacteria including Enterobacter species, Escherichia coli, Morganella Morganii; Proteus Mirabilis, Proteus vulgaris, and Providencia rettgeri. Pseudomonas species are generally resistant to the drug. Nalidixic acid is bactericidal and is effective over the entire urinary pH range. Conventional chromosomal resistance to nalidixic acid taken in full dosage has been reported to emerge in approximately 2 to 14 percent of patients during treatment; however, bacterial resistance to nalidixic acid has not been shown to be transferable via R factor.

Relif Absorption

Following oral administration, nalidixic acid is rapidly absorbed from the gastrointestinal tract. Bioavailability is approximately 96%. Absorption may be delayed if taken with antacids.

Relif side effects and Toxicity

ORAL (LD50): Acute: 1160 mg/kg [Rat]. 572 mg/kg [Mouse]. Toxic psychosis, convulsions, increased intracranial pressure, or metabolic acidosis may occur in patients taking more than the recommended dosage. Vomiting, nausea, and lethargy may also occur following overdosage.

Relif Patient Information

Relif Organisms Affected

Enteric bacteria and other eubacteria